U.S. markets close in 4 hours 13 minutes

Four Healthcare Stocks Making Moves on Monday

CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The future of the healthcare stock market, and the medical sector in its entirety, is largely dependent on whether medical experts and healthcare professionals are aptly prepared to meet the growing demands of patients. According to recent projections, reports suggest the world population will reach 8.6 billion over the next ten years, and each and every one of those people will need access to qualitative healthcare. As companies in the healthcare sector work to develop innovative technologies for their patients, these efforts may create potential opportunities for investors looking to the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Axovant Sciences Ltd (AXGT), Tonix Pharmaceuticals Holding Corp (TNXP), and Cellect Biotechnology Ltd (APOP) are 4 healthcare companies looking to kick off a strong week of trading.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care. Whereas some companies have cut corners to shed costs in their operations, Premier Health has made it clear that they will go the extra mile to provide for their patients.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced last week that it will be working with NexTech AR solutions to explore bringing augmented reality technology to its patient-centric healthcare app. Utilizing AR as a learning tool in training healthcare professionals creates a highly engaging and immersive educational experience which aids in retention and how well complex concepts can be grasped. For patients, AR can potentially empower them to play a more proactive role in their own care through aiding in self-diagnosis.

Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), commented, "at Premier Health we pride ourselves in being at the forefront of changes in healthcare, so we are thrilled to be a part of the future of healthcare by enabling state of the art technological advancements to our patient-centric telemedicine app. AR has the potential to revolutionize both the access to data and the delivery of healthcare."

For More Information On Premier Health Group, Click Here

Axovant Sciences Ltd (AXGT), a clinical-stage company developing innovative gene therapies, today reported 3-month data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson's disease. The cohort consisted of two patients with advanced Parkinson's disease who received a one-time administration of the lowest dose of AXO-Lenti-PD (4.2x106 TU).

Following the announcement, Dr. Gavin Corcoran, Executive Vice President of Research and Development for Axovant, said, "our focus in this first cohort of the SUNRISE-PD study was on the safety and tolerability of AXO-Lenti-PD, as well as the evaluation of efficacy using well-validated, objective measures. These early data support the safety of the lowest dose of AXO-Lenti-PD, similar to what was observed with the earlier generation construct, ProSavin, and also suggest substantially greater biological activity than the highest dose of ProSavin previously tested."

For More Information On Axovant Sciences Ltd, Click Here

Tonix Pharmaceuticals Holding Corp (TNXP), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat neuropsychiatric conditions, announced last week that the European Patent Office (EPO) issued European Patent No. 3246031 to the Company on February 27, 2019. The patent, "Method for Treating Neurodegenerative Dysfunction," claims the use of TNX-601, or tianeptine oxalate and other salts, for treating neurocognitive dysfunction associated with corticosteroid treatment.

Seth Lederman, President, and CEO of Tonix said, "the grant of this European method of use patent is another step in expanding the patent portfolio for TNX-601. Tianeptine oxalate, or TNX-601, is an important product in our pipeline and is being developed not only for steroid-induced neurocognitive impairment but also as a daytime treatment for a post-traumatic stress disorder. We are conducting a non-IND human pharmacokinetic study of a proprietary tianeptine oxalate formulation and expect to have data in the second half of this year."

For More Information On Tonix Pharmaceuticals Holding Corp, Click Here

Cellect Biotechnology Ltd (APOP), a developer of novel stem cell production technology, announced in early-February that it had entered into a collaborative partnership with Washington University, to determine the safety and tolerability in a U.S. Phase I/II study using ApoGraft™ for bone marrow transplantations.

Shai Yarkoni, Chief Executive Officer of Cellect, commented, "we have already reported positive preliminary results for a trial being conducted outside of the U.S., and I believe the collaborative efforts with a leading U.S.-based institution may advance and heighten awareness of our technology. We believe Cellect's ApoGraft™ stem cell selection technology has the potential to improve the lives of millions of patients and be a game changer in bone marrow transplantation - the largest multi-billion-dollar segment of cell therapy in the U.S."

For More Information on Cellect Biotechnology Ltd, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.Please click here for full disclaimer.

Contact Information:


SOURCE: StockPrice.com

View source version on accesswire.com: